RecruitingPhase 2NCT06528496

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Studying Neuroblastoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Memorial Sloan Kettering Cancer Center
Principal Investigator
Brian Kushner, MD
Memorial Sloan Kettering Cancer Center
Intervention
DANYELZA(biological)
Enrollment
45 enrolled
Eligibility
19 years · All sexes
Timeline
2024 – 2029

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06528496 on ClinicalTrials.gov

Other trials for Neuroblastoma

Additional recruiting or active studies for the same condition.

See all trials for Neuroblastoma →

← Back to all trials